AstraZeneca (NASDAQ: AZN) and Pfizer (NYSE: PFE) -- along with one biotech stock, Exelixis (NASDAQ: EXEL). (AstraZeneca): ...

AstraZeneca has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new treatments for chronic diseases. Britain's largest listed company ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases. The drugmaker will collaborate with CSPC ...

In a brief statement, AZ confirmed that Leon Wang, who is also executive vice president, international, at the pharma group, is "cooperating with an ongoing investigation by Chinese authorities." ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after confirming he was under investigation last week. AZ also said four other ...

AstraZeneca boss Sir Pascal Soriot said in February: 'We all think about Leon and miss him, but the reality is we are not able to talk to him. We are not allowed.' AstraZeneca in deal with China ...

Leon Wang, executive vice-president international and China president of AstraZeneca, addresses a celebration of the company’s 30th anniversary in China, in Wuxi, Jiangsu province, on Friday. [Photo ...

The company hopes to bring innovative drugs and holistic disease management solutions to patients, while contributing to the continued development of the healthcare industry in the BDA, Beijing and ...

Leon Wang, who rose from a foreign language tour guide to become the head of international and China for the FTSE 100 drugmaker, is believed to remain in detention eight months after he was ...

When Pascal Soriot flew in to speak at the Boao Forum in China this year, many expected him to keep a low profile. With ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.